256 related articles for article (PubMed ID: 16959374)
21. Neuropeptide Y and its receptor analogs differentially modulate the immunoreactivity for neuronal or endothelial nitric oxide synthase in the rat brain following focal ischemia with reperfusion.
Chen SH; Cheung RT
J Biomed Sci; 2005; 12(2):267-78. PubMed ID: 15942706
[TBL] [Abstract][Full Text] [Related]
22. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
Walker MW; Wolinsky TD; Jubian V; Chandrasena G; Zhong H; Huang X; Miller S; Hegde LG; Marsteller DA; Marzabadi MR; Papp M; Overstreet DH; Gerald CP; Craig DA
J Pharmacol Exp Ther; 2009 Mar; 328(3):900-11. PubMed ID: 19098165
[TBL] [Abstract][Full Text] [Related]
23. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour.
Scott V; Kimura N; Stark JA; Luckman SM
J Neuroendocrinol; 2005 Jul; 17(7):452-7. PubMed ID: 15946163
[TBL] [Abstract][Full Text] [Related]
24. Involvement of CRF but not NPY in the anxiety regulation via NMDA receptors.
Wierońska JM; Szewczyk B; Pałucha A; Brański P; Smiałowska M
Pol J Pharmacol; 2003; 55(6):1119-24. PubMed ID: 14730109
[TBL] [Abstract][Full Text] [Related]
25. Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats.
Thorsell A; Rimondini R; Heilig M
Neurosci Lett; 2002 Oct; 332(1):1-4. PubMed ID: 12377370
[TBL] [Abstract][Full Text] [Related]
26. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue.
Tovote P; Meyer M; Beck-Sickinger AG; von Hörsten S; Ove Ogren S; Spiess J; Stiedl O
Regul Pept; 2004 Aug; 120(1-3):205-14. PubMed ID: 15177939
[TBL] [Abstract][Full Text] [Related]
27. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats.
Kokare DM; Dandekar MP; Chopde CT; Subhedar N
Brain Res; 2005 May; 1043(1-2):107-14. PubMed ID: 15862523
[TBL] [Abstract][Full Text] [Related]
28. Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues.
Hyland NP; Sjöberg F; Tough IR; Herzog H; Cox HM
Br J Pharmacol; 2003 Jun; 139(4):863-71. PubMed ID: 12813010
[TBL] [Abstract][Full Text] [Related]
29. Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo.
Malmström RE
Br J Pharmacol; 2001 Aug; 133(7):1073-80. PubMed ID: 11487518
[TBL] [Abstract][Full Text] [Related]
30. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions.
Smith-White MA; Hardy TA; Brock JA; Potter EK
Br J Pharmacol; 2001 Feb; 132(4):861-8. PubMed ID: 11181427
[TBL] [Abstract][Full Text] [Related]
31. Distinct effects of NPY13-36, a specific NPY Y2 agonist, in a model of rodent endotoxemia on leukocyte subsets and cytokine levels.
Stadler J; Le TP; Haas P; Nave H
Ann Anat; 2011 Dec; 193(6):486-93. PubMed ID: 22074679
[TBL] [Abstract][Full Text] [Related]
32. Orexigenic effect of the melanocortin MC4 receptor antagonist HS014 is inhibited only partially by neuropeptide Y Y1 receptor selective antagonists.
Kask A; Schiöth HB; Harro J; Wikberg JE; Rägo L
Can J Physiol Pharmacol; 2000 Feb; 78(2):143-9. PubMed ID: 10737677
[TBL] [Abstract][Full Text] [Related]
33. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto L; Emmons A; Holmes IP; Montanari D; Norris R; Walters DJ; Watson SP
Bioorg Med Chem Lett; 2009 Aug; 19(15):4022-5. PubMed ID: 19581086
[TBL] [Abstract][Full Text] [Related]
34. Valence-dependent effects of neuropeptide Y on the expression of conditioned fear and anxiety-like behavior: Involvement of the bed nucleus of the stria terminalis.
Kornhuber J; Zoicas I
Neuropharmacology; 2024 Mar; 246():109847. PubMed ID: 38218578
[TBL] [Abstract][Full Text] [Related]
35. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.
Dumont Y; Cadieux A; Doods H; Pheng LH; Abounader R; Hamel E; Jacques D; Regoli D; Quirion R
Br J Pharmacol; 2000 Mar; 129(6):1075-88. PubMed ID: 10725255
[TBL] [Abstract][Full Text] [Related]
36. Neuropeptide Y Reduces Social Fear in Male Mice: Involvement of Y1 and Y2 Receptors in the Dorsolateral Septum and Central Amygdala.
Kornhuber J; Zoicas I
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576305
[TBL] [Abstract][Full Text] [Related]
37. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety.
Karl T; Burne TH; Herzog H
Behav Brain Res; 2006 Feb; 167(1):87-93. PubMed ID: 16203045
[TBL] [Abstract][Full Text] [Related]
38. Involvement of neuropeptide Y Y1 receptors in the regulation of LH and GH cells in the pituitary of the catfish, Clarias batrachus: an immunocytochemical study.
Mazumdar M; Lal B; Sakharkar AJ; Deshmukh M; Singru PS; Subhedar N
Gen Comp Endocrinol; 2006 Nov; 149(2):190-6. PubMed ID: 16828090
[TBL] [Abstract][Full Text] [Related]
39. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
Gehlert DR; Shaw JL
Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
[TBL] [Abstract][Full Text] [Related]
40. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
